Sarcomas | Specialty

Dr. Catton on Omitting Radiation Therapy in Sarcoma

January 25th 2017

Charles Catton, MD, professor, Department of Radiation Oncology, University of Toronto, discusses the notion of omitting radiation therapy in the treatment of patients with extremity sarcoma.

Dr. May on Olaratumab Activity in Pediatric Bone and Soft Tissue Sarcoma

January 21st 2017

Caitlin May, PhD, postdoctoral research fellowship at Eli Lilly and Company, discusses olaratumab's (Lartruvo) demonstrating anti-tumor activity in models of pediatric bone and soft-tissue sarcoma.

Dr. Kasper on Imatinib in Resistant Progressive Desmoid Tumors

January 20th 2017

Bernd Kasper, MD, PhD, professor, Universitätsmedizin Mannheim, Mannheim, discusses results of a phase II study exploring the efficacy of imatinib (Gleevac) in patients with racist progressive demoed tumors.

Dr. Burgess on Pembrolizumab in Sarcoma

January 17th 2017

In the phase II SARC028 trial, single-agent pembrolizumab (Keytruda) demonstrated antitumor activity in patients with advanced soft tissue and bone sarcomas.

Efforts Continue to Expand Immunotherapy Impact in Sarcoma

January 12th 2017

Researchers are hoping the immunotherapy revolution occurring across several cancer types will extend to the field of sarcoma.

Expert Discusses Factors Associated With Local Control in Ewing Sarcoma

January 9th 2017

According to Dimosthenis Andreou, MD, patients with pelvic Ewing sarcoma have poorer local control and poorer overall survival.

Preclinical Activity With Olaratumab in Sarcoma

January 6th 2017

Caitlin May, PhD, postdoctoral research scientist at Eli Lilly and Company, discusses preclinical activity with olaratumab (Lynparza) in pediatric sarcoma models.

Expert Anticipates Immunotherapy to Open Door to Novel Treatments in Osteosarcoma

January 3rd 2017

According to Nancy Gordon, MD, immunotherapy stands to play a critical role in the treatment of patients with osteosarcoma and lung metastases.

Immunotherapy Agents Emerging as Key Players in Sarcoma

December 16th 2016

Excitement continues to surround the potential role of immunotherapy agents in the treatment of patients with sarcoma, according to Breelyn Wilky, MD.

Expert Praises Predictive Role of Radiomics in Sarcoma

December 15th 2016

Several challenges remain in the treatment landscape of soft tissue sarcoma, a disease whose diagnosis can range from one that is quite indolent for patients, to a more life-threatening, metastatic, aggressive cancer.

TRC105/Pazopanib Combo Shows Promising Antitumor Activity in Advanced Angiosarcoma

December 15th 2016

The combination of TRC105, an endoglin antibody, and pazopanib demonstrated promising antitumor activity in patients with advanced angiosarcoma

Dr. Pollack on the Role of Radiomics in Sarcoma

December 13th 2016

Seth M. Pollack, assistant professor, Division of Oncology, University of Washington, and attending physician, Seattle Cancer Care Alliance, discusses the role of radiomics in the treatment landscape of sarcoma.

Dr. Dimosthenis on Prognosis Factors in Ewing Sarcoma

December 2nd 2016

Dimosthenis Andreou, MD, orthopedic oncologist, University Hospital Münster, discusses prognosis factors in patients with Ewing sarcoma.

Pembrolizumab Antitumor Activity Promises Potential for Sarcoma Subtypes

November 15th 2016

Pembrolizumab reduced the size of tumors in patients with a subtype of soft tissue sarcoma, according to updated interim results from the phase II SARC028, multicenter clinical trial, which were reported at the most recent meeting of the Connective Tissue Oncology Society in Lisbon, Portugal.

Dr. Sankhala on the TRC105/Pazopanib Combination in Angiosarcoma

November 12th 2016

Kumar Sankhala, MD, medical director of Clinical Research, Sarcoma Oncology Center, discusses results of a recent trial looking at the combination of endoglin antibody TRC105 and pazopanib in patients with advanced angiosarcoma.

EC Approves Frontline Olaratumab for Soft Tissue Sarcoma

November 12th 2016

The European Commission has granted an accelerated approval to olaratumab in combination with doxorubicin as a frontline therapy for patients with advanced soft tissue sarcoma, making it the first new therapy for this indication in over 40 years.

Dr. Albertsmeier on the Effect of Radiation on Local Recurrence and OS in Soft Tissue Sarcoma

November 10th 2016

Markus Albertsmeier, MD, surgeon, Ludwig Maximilian University of Munich, discusses a a meta-analysis of the effect of radiation therapy on local recurrence and overall survival in patients with soft tissue sarcoma.

Final Thoughts on STS

November 8th 2016

Toxicity of Olaratumab and Doxorubicin

November 8th 2016

Sequencing with Olaratumab in STS

November 8th 2016